Abstract
Dilated cardiomyopathy (DCM) in children is a severe myocardial disease characterized by enlargement of the left ventricle or both ventricles with impaired contractile function. DCM can cause adverse consequences such as heart failure, sudden death, thromboembolism, and arrhythmias. This article reviews the latest advances in genotype and phenotype research in pediatric DCM. With the development of gene sequencing technologies, considerable progress has been made in genetic research on DCM. Research has shown that DCM exhibits notable genetic heterogeneity, with over 100 DCM-related genes identified to date, primarily involving functions such as calcium handling, the cytoskeleton, and ion channels. As human genomic variations are linked to phenotypes, DCM phenotypes are influenced by numerous genetic variations across the entire genome. Children with DCM display high genetic heterogeneity and are characterized by early onset, rapid disease progression, and poor prognosis. The genetic architecture of pediatric DCM markedly differs from that of adult DCM, necessitating analyses through clinical phenotyping, familial cosegregation studies, and functional validation. Clarifying the genotype-phenotype relationship can improve diagnostic accuracy, enhance prognosis, and guide follow-up treatment for genotype-positive and phenotype-negative patients identified through genetic testing, providing new insights for precision medicine. Future research should further explore novel pathogenic genes and mutations and strengthen genotype-phenotype correlation analyses to facilitate precise diagnosis and treatment of DCM in children.
Introduction
Dilated cardiomyopathy (DCM) in children is a myocardial disease characterized by enlargement of the left ventricle or both ventricles, accompanied by systolic dysfunction (). DCM is one of the most common causes of heart failure in children, accounting for approximately 30%–50% of cases (). Pediatric DCM progresses rapidly and has a poor prognosis, with a 5-year survival rate of only 50%–60% and with most deaths resulting from progressive heart failure and its complications (). The etiology of pediatric DCM is diverse and includes genetic, infectious, metabolic, toxic, and idiopathic causes. Approximately 30%–50% of pediatric patients with DCM have pathogenic gene mutations, primarily involving genes encoding sarcomere proteins, ion channels, Z-disc proteins, and nuclear envelope proteins (). Currently, according to the Human Gene Mutation Database and Online Mendelian Inheritance in Man database,over 100 genes have been identified to be associated with monogenic hereditary DCM among the pathogenic genes in hereditary/familial DCM. These include TTN, LMNA, DSP, PLN, FLNC, RBM20, SCN5A, MYH7, MYBPC3, and others (, ). However, after in-depth data analysis, the associations of some of these genes with DCM were not supported. In recent years, with advancements in research on additional genes and genotype-phenotype correlations, phenotypic overlap and dynamic changes in DCM phenotypes have been discovered. Genetic heterogeneity makes it challenging to accurately classify DCM and guide clinical decision-making, thus posing challenges for traditional DCM diagnostic methods (, ). There are both similarities and significant differences between DCM and hypertrophic CM (HCM). There is notable phenotypic overlap between arrhythmogenic CM (ACM) and DCM, with specific genes such as LMNA, SCN5A, FLNC, RBM20, PLN, DSP, and DES potentially causing ACM (). Clarifying genotype-phenotype relationships can enable rapid and precise interpretation of candidate variants in pediatric DCM and greater understanding of its specific variant spectrum, which is crucial for guiding clinical treatment strategies and developing new therapeutic approaches (). Although understanding of the genotypes and phenotypes of pediatric DCM continues to deepen, several issues remain unresolved. This article reviews the latest advances in genotype and phenotype research in pediatric DCM and discusses future research directions with the aim of providing new insights for precision medicine in pediatric DCM.
Figure 1
Figure 2
Table 1
| Functional Group | Gene symbol | Gene Name | Mode of inheritance | Classification | Phenotype | Ref. |
|---|---|---|---|---|---|---|
| Sarcomere | TTN | Titin | AD | Definitive | Cardiomyocyte dysfunction, Left ventricular reverse remodeling, Neuromuscular disorders, Myopathy | (, , , ) |
| MYH7 | Myosin Heavy Chain 7 | AD | Definitive | Myocardial contractile dysfunction, Left ventricular reverse remodeling, Heart failure | (, , ) | |
| MYBPC3 | Myosin Binding Protein C 3 | AD | Limited | Systolic and diastolic dysfunction | () | |
| Nuclear Envelope | LMNA | Lamin A/C | AD | Definitive | Arrhythmias and conduction system disorders, Sudden cardiac death, Neuromuscular disorders, Myopathy | (, , ) |
| Cytoskeleton | FLNC | Filamin C | AD | Definitive | Muscle cell dysfunction, Ventricular arrhythmias, Myocardial fibrosis, Sudden cardiac death, Left ventricular regional wall motion abnormalities | (, , ) |
| DES | Desmin | AD | Definitive | Muscle cell dysfunction | (, ) | |
| Ion channels | SCN5A | Sodium Voltage-Gated Channel Alpha Subunit 5 | AD | Definitive | Ventricular enlargement, Decreased myocardial contractility, Arrhythmia | (, ) |
| Desmosomes | DSP | Desmoplakin | AD | Definitive | Skin and hair abnormalities, Malignant arrhythmia | (, ) |
| Sarcoplasmic reticulum | PLN | Phospholamban | AD | Moderate | Arrhythmia | () |
| Z-disk | BAG3 | BAG Cochaperone 3 | AD | Definitive | Skeletal muscle disorders | (, ) |
| Transcriptional regulation | RBM20 | RNA Binding Motif Protein 20 | AD | Definitive | Early-onset heart failure, Ventricular arrhythmia | (–) |
Genotype and related phenotype in pediatric dilated cardiomyopathy.
Genetic architecture of pediatric DCM
When comparing the genetic composition of DCM in children and adults, although the guidelines recommend genetic testing, there are significant differences in actual clinical practice (Figure 1). In DCM, the presence of variants of uncertain significance (VUS) alone [odds ratio [OR] 4.0, 95% confidence interval [CI] 1.9–8.3] and in combination with pathogenic variants (OR 5.2, 95% CI: 1.7–15.9) is associated with major adverse cardiac events (). Studies have shown that children with cardiomyopathy have a higher incidence of neuromuscular diseases, congenital metabolic defects, mitochondrial diseases, and malformation syndromes (). However, due to the lack of large-scale clinical studies, understanding of the genetic composition of pediatric DCM is limited, and the existence of child-specific DCM pathogenic genes cannot be ruled out. Pediatric DCM exhibits high genetic heterogeneity with a higher number of rare variants, most of which are VUS. This necessitates analyses using clinical phenotyping, familial cosegregation studies, and functional validation (). A Finnish single-center study conducted a 20-year follow-up of 66 children with DCM and found that 39% of the cases had at least one disease-related gene mutation. These diseases included metabolic disorders, sarcomere-related diseases, and various other syndromes. The predominant mutations were missense variants (91.5%) and loss-of-function mutations (5.4%). This Finnish single-center study reported that NRAP is a new cause of severe DCM and other atypical clinical phenotypes in children. PPA2 deficiency involving sudden death may lead to DCM, and junctophilin-2 variants may cause recessive DCM with childhood onset ().
Mutations in the sarcomere-related genes (TTN, MYH7, and MYBPC3) are common in DCM. Studies have found that approximately 10%–13% of patients aged 2–18 years have TTN variants. In DCM cohorts, mutations in genes such as BAG3, CRYAB, and DES can be observed, with some children showing evidence of skeletal muscle involvement (, ). These data indicate genotype-phenotype correlations, emphasizing the importance of genotype-directed therapy in pediatric DCM. However, Canadian literature suggests that the incidence of TTN-truncating variants (TTNtv) is higher in adult DCM patients than in pediatric DCM patients. Compared to adults, pediatric DCM patients have a lower variant burden of channelopathy genes ().
In a North American multi-center study, genomic testing was conducted on 279 pediatric and adolescent patients with DCM (<18 years old) from 14 medical institutions in the United States and Canada. In this pediatric DCM cohort, no pathogenic/likely pathogenic gene had a frequency exceeding 4%. The frequencies of pathogenic/likely pathogenic variants of MYH7, MYBPC3, TNNT2, and RBM20 were similar to those in adult DCM. However, the frequencies of variants in TTN and LMNA were lower than those in adult patients with DCM ().
A retrospective analysis was conducted on 299 pediatric patients with DCM (aged < 18 years) who received treatment at the Children's Hospital of Chicago in the United States between 2007 and 2016. The study found that the genetic architecture differed from that of adults; 37% of pediatric patients with DCM had pathogenic/likely pathogenic gene mutations in sarcomere-related genes. Mutations in LMNA, RBM20, and PLN, which are common in adult DCM, were found to have a lower frequency in pediatric DCM. Additionally, the study emphasized the age-dependent risk associated with TTNtv), which were associated with a later age of onset (average age at initial diagnosis: 9.7 years). TTNtv carriers had a poor prognosis, 60% of patients carrying TTNtv ultimately die or undergo heart transplantation ().
Genotype insights in relation to pediatric DCM
Pediatric DCM is characterized by enlargement of the left or both ventricles and reduced contractile function (). TTN is located on chromosome 2q31 and contains 364 exons. Extensive mRNA splicing can produce various titin isoforms, with N2B and N2BA being the main cardiac-related isoforms (). TTN encodes titin, which is the largest protein in the muscles and is crucial for the structure and function of cardiomyocytes (). TTN mutations have the highest detection rate in pediatric patients with DCM and are an important genetic factor in pediatric DCM (). TTN-related DCM usually follows an autosomal-dominant inheritance pattern; however, complex inheritance patterns also exist (), with TTNtv being the most common (). TTNtv mutations occur predominantly in the A-band region, with smaller proportions occurring in the I-band, Z-disc, and M-line regions. Children with TTNtv mutations in the A-band or M-line regions have a poor prognosis (). DCM caused by TTN mutations exhibits significant phenotypic variability. Even within the same family, there are considerable differences in disease severity and age of onset (). In adult patients with DCM, TTNtv are not uniformly distributed but rather cluster in the A-band region (p = 3.4 × 10−4p = 3.4 × 10−4) (p = 3.5 × 10−3−3p = 3.5 × 10−3). However, this clustering is not observed in pediatric patients ().
MYH7 encodes the myosin protein, which consists of 1,935 amino acids. Myosin is primarily expressed in myocardium and type 1 skeletal muscle fibers and is a important component of the human ventricular system. It plays a crucial role in supplying energy to cardiomyocytes and in maintaining intracellular and extracellular Ca2+ concentrations (). MYH7 mutations can impair myocardial contractile function, resulting in DCM (). In pediatric patients, pathogenic variants in the MYH7 gene are not evenly distributed but mainly cluster in the myosin head and neck regions (Kolmogorov–Smirnov goodness of fit test: p = 8.4 × 10−4, p = 8.4 × 10−4). In adults, variants are primarily concentrated in the myosin head and neck regions, but also appear in the tail region, similar to the reference population ().
MYBPC3 encodes myosin-binding protein C and is the second most common pathogenic gene in DCM after MYH7. It plays a crucial role in maintaining myocardial sarcomere structure and regulating myocardial contraction (). Mutations in MYBPC3 can lead to the abnormal binding of protein C, resulting in myocardial contraction and relaxation dysfunction (). TNNT2 and TNNI3 encode troponins T and I, respectively. These genes encode key proteins involved in myocardial contractions. Mutations in these genes typically lead to impaired myocardial contractile function, thereby causing DCM (, ). TPM1 encodes the cardiac-specific α-chain of tropomyosin. Mutations in this gene affect the assembly and function of myofilaments, leading to decreased myocardial contractility (). Variants in MYBPC3 cluster mainly in the C5, C7, and C10 regions, with no significant differences between children and adults ().
LMNA is located on chromosome 1q21.1–21.3, and contains 12 exons. It encodes type A nuclear lamins, primarily lamins A/C. Vertebrate nuclear lamins include A and B forms. Human lamin A/C produces three type A isoforms through alternative splicing (, ). Mutations in LMNA can lead to various cardiac diseases, including DCM, arrhythmias, and conduction system diseases (). LMNA-related DCM typically has an earlier age of onset, faster disease progression, and poorer prognosis. DCM caused by LMNA mutations is often accompanied by arrhythmias and conduction system abnormalities, which increase the risk of sudden death in patients (). Currently, the treatment for LMNA-related DCM includes standard heart failure therapy and implantable cardioverter-defibrillator (ICD) implantation to prevent sudden death. LMNA is the only gene in the current guidelines with a Class I recommendation for ICD implantation ().
FLNC encodes the actin-binding protein filamin C, which plays important structural and signaling roles in muscle cells (). Mutations in FLNC can lead to abnormal myofilament structures and muscle cell dysfunction, resulting in cardiomyopathy (). Studies have shown that FLNC mutations are significantly associated with pediatric DCM. Compared to the average clinical course of DCM, FLNC-related DCM is more malignant and characterized by a high risk of ventricular arrhythmias, myocardial fibrosis, and sudden cardiac death. The average age of onset is 39.7 ± 14.5 years, and FLNC-related DCM is more commonly found in adults (). However, a pediatric study discovered biallelic FLNC variants in a family with previously unreported pediatric DCM. Biallelic FLNC variants can lead to congenital DCM (). Understanding the role of FLNC may provide new insights for the development of targeted therapeutic strategies ().
SCN5A encodes the α-subunit of the cardiac sodium channel, which plays a crucial role in determining the action potential of cardiomyocytes (). Mutations in the SCN5A gene have been confirmed to be associated with DCM. These mutations can lead to abnormal sodium channel function, thereby affecting myocardial contraction (). Pediatric patients with DCM carrying SCN5A mutations may present with symptoms such as ventricular enlargement, reduced contractile function, and arrhythmias (, ). Certain SCN5A mutations may also be associated with more severe disease progression and poorer prognosis, emphasizing the importance of early genetic testing ().
DSP encode desmoplakin, a protein that plays a crucial role in cell-cell junctions. DSP-related DCM typically follows an autosomal dominant inheritance pattern, although autosomal recessive inheritance has also been reported (, ). Cardiomyopathy caused by DSP mutations is usually associated with arrhythmogenic right ventricular cardiomyopathy (ARVC) or DCM. DCM caused by DSP mutations may be accompanied by skin and hair abnormalities, such as curly hair and palmoplantar keratoderma (). Although DSP mutation-related DCM can occur at any age, cases of childhood-onset have been increasingly reported ().
RBM20 is located on chromosome 10 and contains 14 exons. It encodes a protein of 1,227 amino acids that is primarily expressed in striated muscle, with the highest expression in cardiac muscle and almost no expression in non-muscle tissues. DCM-related RBM20 gene mutations often occur in the arginine/serine-rich (RS) region, leading to loss of function in the expressed protein. Mutations in other regions occur less frequently than those in the RS region but can also reduce RBM20 gene-splicing activity, affecting the expression of regulated genes and leading to DCM (, ). Pediatric patients with DCM carrying RBM20 mutations may present with early onset heart failure and arrhythmias, particularly, an increased risk of ventricular arrhythmias (–).
Research has shown that most genes primarily cause DCM through autosomal-dominant inheritance patterns. Additionally, there have been a few reported cases of DCM caused by autosomal recessive, X-linked, or mitochondrial inheritance patterns ().
Various methods have been applied to further explore new pathogenic genes and mutations. Currently, the main gene-testing strategies include: third-generation sequencing (NGS), genome-wide association studies (GWAS), whole-exome sequencing (WES), and whole-genome sequencing (WGS) (, ).
NGS is a targeted sequencing method that resolves genomic structural variations and complex regions. Customized DCM gene panels can cover 25–50 known DCM genes, including MYH7, MYBPC3, TTN, and LMNA (). However, NGS cannot cover all known DCM genes and cannot detect new genes. GWAS can discover new gene loci associated with the disease by analyzing genotype and phenotype data from a large number of samples, but may miss the effects of rare variants (). WES and WGS can rapidly identify rare pathogenic variants (). Among these, WES is currently the preferred genetic diagnostic method for hereditary DCM. In addition, traditional methods, such as family linkage analysis, also play an important role in identifying pathogenic genes in familial DCM.
Phenotypic diversity
Pediatric DCM exhibits significant genetic heterogeneity, and its clinical manifestations also show notable heterogeneity. The main phenotypic feature of DCM is myocardial injury, with the most prominent characteristics being significant dilation of the left ventricle or both ventricles and progressive decline in cardiac function (). Some children experience symptoms of heart failure, including shortness of breath, fatigue, and reduced exercise tolerance (). Additionally, some children may present with various types of common arrhythmias such as atrial fibrillation and ventricular tachycardia, which can potentially exacerbate symptoms or lead to sudden events ().
In addition to cardiac manifestations, DCM can lead to multisystem involvement. When the nervous system is affected, it can cause motor disorders and cognitive decline (). Studies have also found that some patients may exhibit skeletal muscle involvement such as muscle fatigue, weakness, and elevated muscle enzyme levels, providing an important perspective for understanding the role of the muscle-heart axis in hereditary diseases (). Furthermore, DCM may indirectly affect the endocrine system, particularly through fluid and electrolyte imbalances caused by heart failure ().
The phenotypic diversity of DCM is reflected in its pathogenic mechanisms, clinical manifestations, genetic background, and treatment responses, making it a complex and variable clinical challenge. Complex regulatory mechanisms underlie this process, such as the influence of genetic modifiers and environmental factors on the phenotype (). A deeper understanding of the molecular mechanisms underlying the phenotypic heterogeneity of DCM will facilitate the development of targeted therapeutic approaches.
Genotype-phenotype correlation studies
After reviewing a 76-year timeline in relation to studies on DCM-related gene mutations, the discovery of new DCM-related genes, gene-specific DCM outcomes, and insights into variant-environment interactions was found to have significantly advanced this field. The expansion of genomic phenotype analysis and integration of a series of prognostic factors into the variant environment are crucial (). In Table 1, we summarized genotype and related phenotype in pediatric dilated cardiomyopathy.
Different genotypes have different prognoses
Mutations in different genes can lead to variations in disease progression and prognosis. In pediatric DCM, MYH7-related DCM is characterized by early onset, high phenotypic expressivity, a low incidence of left ventricular reverse remodeling, and frequent progression to end-stage heart failure (). Truncating mutations in MYBPC3 result in loss of protein function,thereby accelerating the progression of cardiomyopathy, which may be significantly associated with disease severity and early onset (). Patients with DCM carrying FLNC mutations may exhibit symptoms such as early onset heart failure and arrhythmia (, ). TTNtv mutations exhibit incomplete and age-dependent penetrance, with variable prognosis in affected children, reaching 100% penetrance by the age of 70 years; the same mutations have also been detected in unaffected relatives (). Although TTNtv are less frequently found in pediatric cases, studies have shown a similar prevalence in adolescents and adults, suggesting that multiple clinical and genetic risk factors rather than a single TTNtv are required for its manifestation (). Hasselberg et al. () found that LMNA mutation-related DCM is a highly pathogenic and age-dependent malignant disease, with affected children prone to arrhythmias and sudden death. These patients have a high incidence of adverse cardiac events and rapid disease progression, with some developing arrhythmias before left ventricular systolic dysfunction is observed. This indicates that genotype information can predict the clinical outcomes in affected children, aiding in the development of individualized treatment strategies.
Heterogeneity exists in the same genotype
There may be significant differences in the phenotypic expression even among individuals carrying the same gene mutation. This phenotypic heterogeneity can be caused by various factors including environmental factors, epigenetic regulation, and genetic background (). For example, Tharp et al. () found that the phenotype and severity of DCM are related to the location of TTNtv, with TTNtv mutations frequently occurring in the A-band region. In terms of sex, males carrying TTNtv were found to be associated with more severe clinical phenotypes and adverse clinical outcomes than females. Furthermore, patients with variants in the exon 11 region (c.2721–2760) of RBM20 had a higher probability of developing DCM than those with variants in the exon 9 region (c.1881–1920) (). Male carriers of RBM20 variants were more likely to progress to end-stage heart failure than female carriers (). However, sex differences were not significant in pediatric and adolescent cohorts. In addition, chemotherapeutic drugs can induce or exacerbate TTNtv mutation-related DCM in children. Nonsense variants of TTN are more common in patients with DCM, whereas frameshift termination and missense variants are more common in patients with neuromuscular and myocardial skeletal disorders ().
Genotype and electrocardiogram (ECG) abnormalities
Numerous children with DCM exhibit ECG abnormalities, such as T-wave changes, left bundle branch block, atrioventricular conduction abnormalities, and supraventricular arrhythmias (). Children with ECG abnormalities have a higher mortality rate. Certain genetic causes of DCM result in malignant arrhythmic phenotypes. Autonomic nervous system imbalance and impaired myocardial repolarization homogeneity are two major underlying mechanisms of arrhythmia in patients with DCM (). Laminopathies are often associated with prolonged PR intervals on ECG, which are indicators of cardiac conduction disorders. DCM associated with DSP mutations typically has a poor prognosis and may lead to malignant arrhythmias.
Patients with DCM carrying variants of LMNA, PLN, FLNC, and RBM20 have an increased risk of developing arrhythmias. Younger patients with LMNA-related DCM and RBM20-related DCM show increased expression levels of arrhythmia-related cardiomyopathy. LMNA-related DCM exhibits a highly penetrant arrhythmic phenotype accompanied by multiple muscle involvement. Taylor et al. () reported that patients with LMNA-related DCM simultaneously experienced muscle involvement and arrhythmias, particularly chronic arrhythmias. LMNA variants account for up to 33% of DCM cases with atrioventricular conduction block (). Similarly, patients carrying the PLN R14del founder variant typically develop ventricular arrhythmia and end-stage heart failure at a young age (). Studies have found that left ventricular regional wall motion abnormalities are more common in DSP/FLNC genotypes, and these genotypes cause extensive regional left ventricular damage ().
Genotyping and neuromuscular diseases
The dilated phenotype is the most common cardiomyopathic manifestation in neuromuscular diseases (). In pediatric neuromuscular diseases (NMD), particularly in dystrophies, abnormalities in the splicing of the CUG binding protein (CUG-BP) and muscle blind-like protein (MBNL) interfere with cellular signaling, resulting in toxic effects on muscle metabolism and RNA processing. This may cause changes in the cardiac structure and function, potentially resulting in the early onset of dilated cardiomyopathy (DCM) (). Children with DCM who carry specific genotypes are prone to developing concurrent skeletal myopathies. Relevant neuromuscular symptoms in patients or relatives are important criteria for genetic analysis, because variants of LMNA are associated with DCM related to neuromuscular diseases (limb-girdle muscular dystrophy) (). Emery-Dreifuss muscular dystrophy (EDMD) is closely related to dilated cardiomyopathy (DCM). In a study of 53 patients, mutations in LMNA were identified as a major cause, with 12 patients exhibiting significant cardiac involvement and 41 exhibiting muscle weakness. Therefore, screening for LMNA mutations is crucial in familial and sporadic cases associated with EDMD and DCM ().
The impact of TTNtv extends beyond the heart, with 46%–57% of children with DCM and congenital heart disease exhibiting TTN-related neuromuscular diseases of varying severity (). Sofie et al. () found that TTNtv carriers had a higher skeletal muscle fat content than patients with non-TTNtv hereditary DCM. Muscle biopsies in 62% of TTNtv carriers showed characteristics of skeletal muscle involvement, manifesting as well-aligned Z-lines and T-tubules, but with uneven and discontinuous M-lines, accompanied by excessive glycogen deposition. This was surrounded by autophagosomes, lysosomes, and mitochondrial autophagy with abnormal mitochondria, suggesting that patients with DCM with monoallelic TTNtv simultaneously have mild skeletal myopathy. Phenotype overlap may also occur in genes such as DES and LMNA, where DCM may be accompanied by skeletal myopathy ().
Treatment strategies and future research directions
Over the past few decades, while significant progress has been made in the treatment of DCM, many challenges remain. Transcription factors play a crucial role in dilated cardiomyopathy (DCM),may represent novel therapeutic targets.For instance, GATA4 and MEF2C are involved in the regulation of cardiac remodeling, and changes in their expression may lead to alterations in myocardial structure and function (). Recent studies have also identified a correlation between mutations in the TBX5 gene and an increased risk of cardiac developmental defects and DCM. Additionally, TBX5 is associated with certain neuromuscular diseases, which often involve cardiac complications, including DCM (, ). Cardiovascular magnetic resonance can help identify the subclinical forms of the disease, facilitating a deeper understanding of the diverse phenotypes of DCM (, ) and the genes affecting pediatric DCM, with gene therapy offering a potential avenue for treating pediatric DCM (). Cardiac function can be improved by modifying or replacing pathogenic genes in the cardiomyocytes to restore normal gene function. However, gene therapy is still in its early stages, and more clinical trials are necessary to verify the efficacy and safety of these therapeutic strategies ().
Personalized medicine is becoming increasingly important in the treatment of pediatric DCM. Studies have indicated that patients with different phenotypes respond differently to specific treatments. For example, Verdonschot et al. () found differences in prognoses among different phenotype groups in DCM. Among the four phenotypic groups identified in their study, the arrhythmic group had the poorest prognosis and was highly susceptible to life-threatening malignant arrhythmias. After 12 months of regular drug therapy, 52.5% of patients experienced left ventricular reverse remodeling (LVRR), with the severe systolic dysfunction group showing the highest LVRR rate. Therefore, developing individualized treatment plans based on phenotypes and comorbidities of different patients can significantly improve treatment efficacy and patient quality of life.
Regarding future research directions, efforts should be made to expand sample sizes and establish more extensive genetic and phenotypic databases to achieve comprehensive assessments (). At the same time, long-term follow-up of patients with DCM is crucial. Simultaneously,long-term follow-up allows for the evaluation of the effect of how different genotypes on disease progression and enables timely adjustments to treatment plans, thereby improving prognosis ().
Conclusion
Pediatric DCM exhibits significant genetic heterogeneity, with variations in the expression of multiple genes being closely associated with its development in childhood (). These genes affect myocardial function through different pathways and can lead to diverse clinical phenotypes (). This variability may result from the combined effects of gene-environment interactions, epigenetic regulation, and other unknown genetic factors (Figure 2). Personalized treatment plans targeting specific genotypes are promising for improving the prognosis and quality of life of affected children. The development of technologies such as GWAS and NGS has considerably advanced understanding of the action mechanisms of pediatric DCM (). Gene therapy has shown promising results in animal models (). However, their safety and efficacy require further validation through clinical trials. In the future, large-sample multicenter prospective cohort studies will help deepen the understanding of the genetic mechanisms underlying pediatric DCM.
In conclusion, research on the genotypes and phenotypes of pediatric DCM provides crucial perspectives and information for understanding its pathological mechanisms, thereby offering new hope for children with DCM. However, major challenges remain. We anticipate that as research progresses, these challenges can be addressed with the development of new therapeutic approaches for this complex disease.
Statements
Author contributions
YD: Conceptualization, Data curation, Methodology, Writing – original draft. YW: Data curation, Investigation, Writing – review & editing. YF: Conceptualization, Supervision, Writing – review & editing. BH: Conceptualization, Supervision, Writing – review & editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China General Project (81873498), Mount Taishan Scholar Distinguished Expert (No. ts201511099), Shandong Provincial Natural Science Foundation General Project (ZR2023MH052, ZR2023MH298) and Jinan Science and Technology Plan (202134015).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
LipshultzSELawYMAsante-KorangAAustinEDDipchandAIEverittMDet alCardiomyopathy in children: classification and diagnosis: a scientific statement from the American heart association. Circulation. (2019) 140(1):e9–e68. 10.1161/CIR.0000000000000682
2.
LeeTMHsuDTKantorPTowbinJAWareSMColanSDet alPediatric cardiomyopathies. Circ Res. (2017) 121(7):855–73. 10.1161/CIRCRESAHA.116.309386
3.
JordanEPetersonLAiTAsatryanBBronickiLBrownEet alEvidence-based assessment of genes in dilated cardiomyopathy. Circulation. (2021) 144(1):7–19. 10.1161/CIRCULATIONAHA.120.053033
4.
HarakalovaMKummelingGSammaniALinschotenMBaasAFvan der SmagtJet alA systematic analysis of genetic dilated cardiomyopathy reveals numerous ubiquitously expressed and muscle-specific genes. Eur J Heart Fail. (2015) 17(5):484–93. 10.1002/ejhf.255
5.
McNallyEMMestroniL. Dilated cardiomyopathy: genetic determinants and mechanisms. Circ Res. (2017) 121(7):731–48. 10.1161/CIRCRESAHA.116.309396
6.
HaasJFreseKSPeilBKloosWKellerANietschRet alAtlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J. (2015) 36(18):1123–35a. 10.1093/eurheartj/ehu301
7.
TowbinJAMcKennaWJAbramsDJAckermanMJCalkinsHDarrieuxFCCet al2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. (2019) 16(11):e301–e72. 10.1016/j.hrthm.2019.05.007
8.
WangYDobrevaG. Epigenetics in LMNA-related cardiomyopathy. Cells. (2023) 12(5):783. 10.3390/cells12050783
9.
EldemireRMestroniLTaylorMRG. Genetics of dilated cardiomyopathy. Annu Rev Med. (2024) 75:417–26. 10.1146/annurev-med-052422-020535
10.
MoralesAKinnamonDDJordanEPlattJVattaMDorschnerMOet alVariant interpretation for dilated cardiomyopathy: refinement of the American college of medical genetics and genomics/ClinGen guidelines for the DCM precision medicine study. Circ Genom Precis Med. (2020) 13(2):e002480. 10.1161/CIRCGEN.119.002480
11.
BursteinDSGaynorJWGriffisHRitterAConnorMJORossanoJWet alGenetic variant burden and adverse outcomes in pediatric cardiomyopathy. Pediatr Res. (2021) 89(6):1470–6. 10.1038/s41390-020-1101-5
12.
VasilescuCOjalaTHBrilhanteVOjanenSHinterdingHMPalinEet alGenetic basis of severe childhood-onset cardiomyopathies. J Am Coll Cardiol. (2018) 72(19):2324–38. 10.1016/j.jacc.2018.08.2171
13.
WareSMBhatnagarSDexheimerPJWilkinsonJDSridharAFanXet alThe genetic architecture of pediatric cardiomyopathy. Am J Hum Genet. (2022) 109(2):282–98. 10.1016/j.ajhg.2021.12.006
14.
KhanRSPahlEDellefave-CastilloLRychlikKIngAYapKLet alGenotype and cardiac outcomes in pediatric dilated cardiomyopathy. J Am Heart Assoc. (2022) 11(1):e022854. 10.1161/JAHA.121.022854
15.
AkinrinadeOLesurfR, Genomics England Research C, LougheedJMondalTSmytheJet alAge and sex differences in the genetics of cardiomyopathy. J Cardiovasc Transl Res. (2023) 16(6):1287–302. 10.1007/s12265-023-10411-8
16.
TowbinJALoweAMColanSDSleeperLAOravEJClunieSet alIncidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. (2006) 296(15):1867–76. 10.1001/jama.296.15.1867
17.
TharpCAHaywoodMESbaizeroOTaylorMRGMestroniL. The giant protein Titin’s role in cardiomyopathy: genetic, transcriptional, and post-translational modifications of TTN and their contribution to cardiac disease. Front Physiol. (2019) 10:1436. 10.3389/fphys.2019.01436
18.
HermanDSLamLTaylorMRWangLTeekakirikulPChristodoulouDet alTruncations of titin causing dilated cardiomyopathy. N Engl J Med. (2012) 366(7):619–28. 10.1056/NEJMoa1110186
19.
PughTJKellyMAGowrisankarSHynesESeidmanMABaxterSMet alThe landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genet Med. (2014) 16(8):601–8. 10.1038/gim.2013.204
20.
RobertsAMWareJSHermanDSSchaferSBaksiJBickAGet alIntegrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci Transl Med. (2015) 7(270):270ra6. 10.1126/scitranslmed.3010134
21.
SchaferSde MarvaoAAdamiEFiedlerLRNgBKhinEet alTitin-truncating variants affect heart function in disease cohorts and the general population. Nat Genet. (2017) 49(1):46–53. 10.1038/ng.3719
22.
TayalUNewsomeSBuchanRWhiffinNHallidayBLotaAet alPhenotype and clinical outcomes of titin cardiomyopathy. J Am Coll Cardiol. (2017) 70(18):2264–74. 10.1016/j.jacc.2017.08.063
23.
GaoYPengLZhaoC. MYH7 In cardiomyopathy and skeletal muscle myopathy. Mol Cell Biochem. (2024) 479(2):393–417. 10.1007/s11010-023-04735-x
24.
MoritaHRehmHLMenessesAMcDonoughBRobertsAEKucherlapatiRet alShared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med. (2008) 358(18):1899–908. 10.1056/NEJMoa075463
25.
MarstonSCopelandOGehmlichKSchlossarekSCarrierL. How do MYBPC3 mutations cause hypertrophic cardiomyopathy?J Muscle Res Cell Motil. (2012) 33(1):75–80. 10.1007/s10974-011-9268-3
26.
CarrierLMeariniGStathopoulouKCuelloF. Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology. Gene. (2015) 573(2):188–97. 10.1016/j.gene.2015.09.008
27.
KimuraAHaradaHParkJENishiHSatohMTakahashiMet alMutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet. (1997) 16(4):379–82. 10.1038/ng0897-379
28.
SorrentinoUGabbiatoICancianiCCalosciDRigonCZuccarelloDet alHomozygous TNNI3 mutations and severe early onset dilated cardiomyopathy: patient report and review of the literature. Genes. (2023) 14(3):748. 10.3390/genes14030748
29.
LynnMLTal GrinspanLHolemanTAJimenezJStromJTardiffJC. The structural basis of alpha-tropomyosin linked (Asp230Asn) familial dilated cardiomyopathy. J Mol Cell Cardiol. (2017) 108:127–37. 10.1016/j.yjmcc.2017.06.001
30.
CapturGArbustiniEBonneGSyrrisPMillsKWahbiKet alLamin and the heart. Heart. (2018) 104(6):468–79. 10.1136/heartjnl-2017-312338
31.
FatkinDMacRaeCSasakiTWolffMRPorcuMFrenneauxMet alMissense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med. (1999) 341(23):1715–24. 10.1056/NEJM199912023412302
32.
PasottiMKlersyCPilottoAMarzilianoNRapezziCSerioAet alLong-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol. (2008) 52(15):1250–60. 10.1016/j.jacc.2008.06.044
33.
HasselbergNEHalandTFSaberniakJBrekkePHBergeKELerenTPet alLamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation. Eur Heart J. (2018) 39(10):853–60. 10.1093/eurheartj/ehx596
34.
van RijsingenIAArbustiniEElliottPMMogensenJHermans-van AstJFvan der KooiAJet alRisk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol. (2012) 59(5):493–500. 10.1016/j.jacc.2011.08.078
35.
Ortiz-GengaMFCuencaSDal FerroMZorioESalgado-ArandaRClimentVet alTruncating FLNC mutations are associated with high-risk dilated and arrhythmogenic cardiomyopathies. J Am Coll Cardiol. (2016) 68(22):2440–51. 10.1016/j.jacc.2016.09.927
36.
AderFDe GrootePReantPRooryck-ThamboCDupin-DeguineDRambaudCet alFLNC Pathogenic variants in patients with cardiomyopathies: prevalence and genotype-phenotype correlations. Clin Genet. (2019) 96(4):317–29. 10.1111/cge.13594
37.
VerdonschotJAJVanhoutteEKClaesGRFHelderman-van den EndenAHoeijmakersJGJHellebrekersDet alA mutation update for the FLNC gene in myopathies and cardiomyopathies. Hum Mutat. (2020) 41(6):1091–111. 10.1002/humu.24004
38.
ReinsteinEGutierrez-FernandezATzurSBormansCMarcuSTayeb-FligelmanEet alCongenital dilated cardiomyopathy caused by biallelic mutations in Filamin C. Eur J Hum Genet. (2016) 24(12):1792–6. 10.1038/ejhg.2016.110
39.
BabanAAlesiVMagliozziMParlapianoGGenoveseSCiceniaMet alCardiovascular involvement in pediatric FLNC variants: a case series of fourteen patients. J Cardiovasc Dev Dis. (2022) 9(10):332. 10.3390/jcdd9100332
40.
RemmeCA. Cardiac sodium channelopathy associated with SCN5A mutations: electrophysiological, molecular and genetic aspects. J Physiol. (2013) 591(17):4099–116. 10.1113/jphysiol.2013.256461
41.
WauchopMRafatianNZhaoYChenWGagliardiMMasseSet alMaturation of iPSC-derived cardiomyocytes in a heart-on-a-chip device enables modeling of dilated cardiomyopathy caused by R222Q-SCN5A mutation. Biomaterials. (2023) 301:122255. 10.1016/j.biomaterials.2023.122255
42.
MaronBJTowbinJAThieneGAntzelevitchCCorradoDArnettDet alContemporary definitions and classification of the cardiomyopathies: an American heart association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation. (2006) 113(14):1807–16. 10.1161/CIRCULATIONAHA.106.174287
43.
RemmeCA. SCN5A Channelopathy: arrhythmia, cardiomyopathy, epilepsy and beyond. Philos Trans R Soc Lond B Biol Sci. (2023) 378(1879):20220164. 10.1098/rstb.2022.0164
44.
ProostVMvan den BergMPRemmeCAWildeAAM. SCN5A-1795insD Founder variant: a unique dutch experience spanning 7 decades. Neth Heart J. (2023) 31(7-8):263–71. 10.1007/s12471-023-01799-8
45.
SmithEDLakdawalaNKPapoutsidakisNAubertGMazzantiAMcCantaACet alDesmoplakin cardiomyopathy, a fibrotic and inflammatory form of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathy. Circulation. (2020) 141(23):1872–84. 10.1161/CIRCULATIONAHA.119.044934
46.
CastellettiSVischerASSyrrisPCrottiLSpazzoliniCGhidoniAet alDesmoplakin missense and non-missense mutations in arrhythmogenic right ventricular cardiomyopathy: genotype-phenotype correlation. Int J Cardiol. (2017) 249:268–73. 10.1016/j.ijcard.2017.05.018
47.
NorgettEEHatsellSJCarvajal-HuertaLCabezasJCCommonJPurkisPEet alRecessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum Mol Genet. (2000) 9(18):2761–6. 10.1093/hmg/9.18.2761
48.
SeidelFHoltgreweMAl-Wakeel-MarquardNOpgen-RheinBDartschJHerbstCet alPathogenic variants associated with dilated cardiomyopathy predict outcome in pediatric myocarditis. Circ Genom Precis Med. (2021) 14(4):e003250. 10.1161/CIRCGEN.120.003250
49.
NishiyamaTZhangYCuiMLiHSanchez-OrtizEMcAnallyJRet alPrecise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy. Sci Transl Med. (2022) 14(672):eade1633. 10.1126/scitranslmed.ade1633
50.
MaatzHJensMLissMSchaferSHeinigMKirchnerMet alRNA-binding protein RBM20 represses splicing to orchestrate cardiac pre-mRNA processing. J Clin Invest. (2014) 124(8):3419–30. 10.1172/JCI74523
51.
CannieDEProtonotariosABakalakosASyrrisPLorenziniMDe StavolaBet alRisks of ventricular arrhythmia and heart failure in carriers of RBM20 variants. Circ Genom Precis Med. (2023) 16(5):434–41. 10.1161/CIRCGEN.123.004059
52.
LongPAEvansJMOlsonTM. Diagnostic yield of whole exome sequencing in pediatric dilated cardiomyopathy. J Cardiovasc Dev Dis. (2017) 4(3):11. 10.3390/jcdd4030011
53.
SettiMMerloMGigliMMunarettoLPaldinoAStolfoDet alRole of arrhythmic phenotype in prognostic stratification and management of dilated cardiomyopathy. Eur J Heart Fail. (2024) 26(3):581–9. 10.1002/ejhf.3168
54.
HershbergerREGivertzMMHoCYJudgeDPKantorPFMcBrideKLet alGenetic evaluation of cardiomyopathy: a clinical practice resource of the American college of medical genetics and genomics (ACMG). Genet Med. (2018) 20(9):899–909. 10.1038/s41436-018-0039-z
55.
GoodwinSMcPhersonJDMcCombieWR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet. (2016) 17(6):333–51. 10.1038/nrg.2016.49
56.
ClarkMJChenRLamHYKarczewskiKJChenREuskirchenGet alPerformance comparison of exome DNA sequencing technologies. Nat Biotechnol. (2011) 29(10):908–14. 10.1038/nbt.1975
57.
OuelletteACMathewJManickarajAKManaseGZahavichLWilsonJet alClinical genetic testing in pediatric cardiomyopathy: is bigger better?Clin Genet. (2018) 93(1):33–40. 10.1111/cge.13024
58.
VillardEPerretCGaryFProustCDilanianGHengstenbergCet alA genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J. (2011) 32(9):1065–76. 10.1093/eurheartj/ehr105
59.
BamshadMJNgSBBighamAWTaborHKEmondMJNickersonDAet alExome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet. (2011) 12(11):745–55. 10.1038/nrg3031
60.
WeintraubRGSemsarianCMacdonaldP. Dilated cardiomyopathy. Lancet. (2017) 390(10092):400–14. 10.1016/S0140-6736(16)31713-5
61.
PuggiaIMerloMBarbatiGRowlandTJStolfoDGigliMet alNatural history of dilated cardiomyopathy in children. J Am Heart Assoc. (2016) 5(7):e003450. 10.1161/JAHA.116.003450
62.
JefferiesJLTowbinJA. Dilated cardiomyopathy. Lancet. (2010) 375(9716):752–62. 10.1016/S0140-6736(09)62023-7
63.
FinstererJStollbergerC. The heart in human dystrophinopathies. Cardiology. (2003) 99(1):1–19. 10.1159/000068446
64.
SchrierRWAbrahamWT. Hormones and hemodynamics in heart failure. N Engl J Med. (1999) 341(8):577–85. 10.1056/NEJM199908193410806
65.
NjorogeJNMangenaJCAribeanaCParikhVN. Emerging genotype-phenotype associations in dilated cardiomyopathy. Curr Cardiol Rep. (2022) 24(9):1077–84. 10.1007/s11886-022-01727-z
66.
de FrutosFOchoaJPNavarro-PenalverMBaasABjerreJVZorioEet alNatural history of MYH7-related dilated cardiomyopathy. J Am Coll Cardiol. (2022) 80(15):1447–61. 10.1016/j.jacc.2022.07.023
67.
Van DriestSLVasileVCOmmenSRWillMLTajikAJGershBJet alMyosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. J Am Coll Cardiol. (2004) 44(9):1903–10. 10.1016/j.jacc.2004.07.045
68.
DunguJNLangleySGHardy-WallaceALiBBarbagalloRMFieldDet alDilated cardiomyopathy: the role of genetics, highlighted in a family with filamin C (FLNC) variant. Heart. (2022) 108(9):676–82. 10.1136/heartjnl-2021-319682
69.
CarruthEDQureshiMAlsaidAKellyMACalkinsHMurrayBet alLoss-of-function FLNC variants are associated with arrhythmogenic cardiomyopathy phenotypes when identified through exome sequencing of a general clinical population. Circ Genom Precis Med. (2022) 15(4):e003645. 10.1161/CIRCGEN.121.003645
70.
WangYHanBFanYYiYLvJWangJet alNext-generation sequencing reveals novel genetic variants for dilated cardiomyopathy in pediatric Chinese patients. Pediatr Cardiol. (2022) 43(1):110–20. 10.1007/s00246-021-02698-8
71.
JolfayiAGKohansalEGhasemiSNaderiNHesamiMMozafaryBazarganyMet alExploring TTN variants as genetic insights into cardiomyopathy pathogenesis and potential emerging clues to molecular mechanisms in cardiomyopathies. Sci Rep. (2024) 14(1):5313. 10.1038/s41598-024-56154-7
72.
BondueAArbustiniEBiancoACiccarelliMDawsonDDe RosaMet alComplex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the working group of myocardial function of the European society of cardiology. Cardiovasc Res. (2018) 114(10):1287–303. 10.1093/cvr/cvy122
73.
MeyerAPBarnettCLMyersKSiskindCEMoscarelloTLoganRet alNeuromuscular and cardiovascular phenotypes in paediatric titinopathies: a multisite retrospective study. J Med Genet. (2024) 61(4):356–62. 10.1136/jmg-2023-109513
74.
TureMBalikHAkinABiliciMNergizA. The relationship between electrocardiographic data and mortality in children diagnosed with dilated cardiomyopathy. Eur J Pediatr. (2020) 179(5):813–9. 10.1007/s00431-020-03569-9
75.
WangMXuYWangSZhaoTCaiHWangYet alPredictive value of electrocardiographic markers in children with dilated cardiomyopathy. Front Pediatr. (2022) 10:917730. 10.3389/fped.2022.917730
76.
TaylorMRFainPRSinagraGRobinsonMLRobertsonADCarnielEet alNatural history of dilated cardiomyopathy due to lamin A/C gene mutations. J Am Coll Cardiol. (2003) 41(5):771–80. 10.1016/S0735-1097(02)02954-6
77.
ArbustiniEPilottoARepettoAGrassoMNegriADiegoliMet alAutosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease. J Am Coll Cardiol. (2002) 39(6):981–90. 10.1016/S0735-1097(02)01724-2
78.
SerpaFFinnCMTahirUA. Navigating the penetrance and phenotypic spectrum of inherited cardiomyopathies. Heart Fail Rev. (2024) 29(5):873–81. 10.1007/s10741-024-10405-x
79.
AugustoJBEirosRNakouEMoura-FerreiraSTreibelTACapturGet alDilated cardiomyopathy and arrhythmogenic left ventricular cardiomyopathy: a comprehensive genotype-imaging phenotype study. Eur Heart J Cardiovasc Imaging. (2020) 21(3):326–36. 10.1093/ehjci/jez188
80.
BabanALodatoVParlapianoGdi MambroCAdorisioRBertiniESet alMyocardial and arrhythmic spectrum of neuromuscular disorders in children. Biomolecules. (2021) 11(11):1578. 10.3390/biom11111578
81.
MaggiLCarboniNBernasconiP. Skeletal muscle laminopathies: a review of clinical and molecular features. Cells. (2016) 5(3):33. 10.3390/cells5030033
82.
BonneGMercuriEMuchirAUrtizbereaABécaneHMRecanDet alClinical and molecular genetic spectrum of autosomal dominant emery-dreifuss muscular dystrophy due to mutations of the lamin A/C gene. Ann Neurol. (2000) 48(2):170–80. 10.1002/1531-8249(200008)48:2%3C170::AID-ANA6%3E3.0.CO;2-J
83.
ReesMNikoopourRFukuzawaAKhoALFernandez-GarciaMAWraigeEet alMaking sense of missense variants in TTN-related congenital myopathies. Acta Neuropathol. (2021) 141(3):431–53. 10.1007/s00401-020-02257-0
84.
SkriverSVKrettBPoulsenNSKragTWalasHRChristensenAHet alSkeletal muscle involvement in patients with truncations of titin and familial dilated cardiomyopathy. JACC Heart Fail. (2024) 12(4):740–53. 10.1016/j.jchf.2023.10.010
85.
JohnsonROtwayRChinEHorvatCOhanianMWilcoxJALet alDMD-associated dilated cardiomyopathy: genotypes, phenotypes, and phenocopies. Circ Genom Precis Med. (2023) 16(5):421–30. 10.1161/CIRCGEN.123.004221
86.
MikšiūnasRLabeitSBironaiteD. Class I and II histone deacetylase inhibitors as therapeutic modulators of dilated cardiac tissue-derived mesenchymal stem/stromal cells. Int J Mol Sci. (2024) 25(12):6758. 10.3390/ijms25126758
87.
ZhangXLQiuXBYuanFWangJZhaoCMLiRGet alTBX5 loss-of-function mutation contributes to familial dilated cardiomyopathy. Biochem Biophys Res Commun. (2015) 459(1):166–71. 10.1016/j.bbrc.2015.02.094
88.
PattersonJCoatsCMcGowanR. Familial dilated cardiomyopathy associated with pathogenic TBX5 variants: expanding the cardiac phenotype associated with Holt-Oram syndrome. Am J Med Genet A. (2020) 182(7):1725–34. 10.1002/ajmg.a.61635
89.
AntonopoulosASXintarakouAProtonotariosALazarosGMiliouATsioufisKet alImagenetics for precision medicine in dilated cardiomyopathy. Circ Genom Precis Med. (2024) 17(2):e004301. 10.1161/CIRCGEN.123.004301
90.
de FrutosFOchoaJPFernandezAIGallego-DelgadoMNavarro-PenalverMCasasGet alLate gadolinium enhancement distribution patterns in non-ischaemic dilated cardiomyopathy: genotype-phenotype correlation. Eur Heart J Cardiovasc Imaging. (2023) 25(1):75–85. 10.1093/ehjci/jead184
91.
HinsonJTChopraANafissiNPolacheckWJBensonCCSwistSet alHEART DISEASE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science. (2015) 349(6251):982–6. 10.1126/science.aaa5458
92.
VerdonschotJAJMerloMDominguezFWangPHenkensMAdriaensMEet alPhenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences. Eur Heart J. (2021) 42(2):162–74. 10.1093/eurheartj/ehaa841
93.
HershbergerREGivertzMMHoCYJudgeDPKantorPFMcBrideKLet alGenetic evaluation of cardiomyopathy-A heart failure society of America practice guideline. J Card Fail. (2018) 24(5):281–302. 10.1016/j.cardfail.2018.03.004
94.
TaylorDOEdwardsLBBoucekMMTrulockEPDengMCKeckBMet alRegistry of the international society for heart and lung transplantation: twenty-second official adult heart transplant report–2005. J Heart Lung Transplant. (2005) 24(8):945–55. 10.1016/j.healun.2005.05.018
95.
MizusawaY. Recent advances in genetic testing and counseling for inherited arrhythmias. J Arrhythm. (2016) 32(5):389–97. 10.1016/j.joa.2015.12.009
96.
BishLTMorineKSleeperMMSanmiguelJWuDGaoGet alAdeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther. (2008) 19(12):1359–68. 10.1089/hum.2008.123
Summary
Keywords
children, dilated cardiomyopathy, genetics, inherited cardiomyopathy, genotype-phenotype correlation
Citation
Dai Y, Wang Y, Fan Y and Han B (2025) Genotype-phenotype insights of pediatric dilated cardiomyopathy. Front. Pediatr. 13:1505830. doi: 10.3389/fped.2025.1505830
Received
03 October 2024
Accepted
21 January 2025
Published
31 January 2025
Volume
13 - 2025
Edited by
Nathalie Jeanne M. Bravo-valenzuela, Federal University of Rio de Janeiro, Brazil
Reviewed by
Cecilia Lazea, University of Medicine and Pharmacy Iuliu Hatieganu, Romania
Yangpo Cao, Southern University of Science and Technology, China
Updates
Copyright
© 2025 Dai, Wang, Fan and Han.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bo Han hanbo35@163.com Youfei Fan fanyoufei0720@126.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.